Skip to main content
. 2015 Dec 21;3(1):29679. doi: 10.3402/jmahp.v3.29679

Fig. 12.

Fig. 12.

The MALEI benchmark for the biopharmaceutical industry and the profile of the hypothetical company X depicted as IAILs by excellence item (n(Biopharma)=47–53).